AI-based 바카라사이트 소개 diagnostic technology poised to drive an innovative paradigm shift in 바카라사이트 소개 diagnostics
[by Yu, Suin] AstraZeneca Korea announced on July 16 that it had recently signed a memorandum of understanding (MOU) with Aivis, an AI-based digital pathology solution startup, at its headquarters in Samseong-dong, Seoul. The agreement aims to establish an AI-driven 바카라사이트 소개 diagnosis ecosystem.
Through this agreement, the two companies intend to actively collaborate in supporting 바카라사이트 소개 diagnostics in accordance with the newly revised 바카라사이트 소개 classification system for breast cancer. Their joint efforts aim to establish a foundation that enables Korean breast cancer patients to access innovative treatment options in a timely manner.
바카라사이트 소개 (human epidermal growth factor receptor 2) is a key protein biomarker that plays a critical role in the growth and proliferation of cancer cells. Among the various cancer types that may exhibit 바카라사이트 소개 expression, breast cancer is particularly influenced by the level of 바카라사이트 소개 expression, as it can significantly impact treatment strategies. Therefore, accurate 바카라사이트 소개 diagnosis is essential for determining the most appropriate therapeutic method for breast cancer patients.
Recently, a revised HER2 classification system has been introduced in the field of breast cancer treatment, expanding beyond the traditional binary categorization of HER2-positive and HER2-negative. This new system includes the concept of ‘HER2 low expression (HER2-low).’ HER2 expression levels in breast cancer are assessed using immunohistochemistry (IHC) testing, and tumors classified as IHC 1+ or IHC 2+ with negative results on in situ hybridization (ISH) are designated as ‘HER2-low.’
This shift reflects a paradigm change in breast cancer treatment, driven by findings from the DESTINY-Breast04 study, which investigated ‘Enhertu (trastuzumab deruxtecan),’ an antibody-drug conjugate (ADC) therapy co-developed and marketed by the multinational pharmaceutical company AstraZeneca and Japan’s Daiichi Sankyo, in the HER2-low expression breast cancer patient group.
This business agreement was established to introduce AI-based 바카라사이트 소개 diagnostic technology in Korea, aiming to enhance the efficiency of interpretation by medical professionals, particularly as more detailed 바카라사이트 소개 diagnoses become necessary for hormone receptor-positive breast cancer patients who were previously classified as 바카라사이트 소개 negative. Traditionally, IHC tests have relied on visual assessment by pathologists, who manually evaluate the degree of cell membrane staining in cancerous tissue using a microscope or digital screen. However, this method presents several limitations, including lengthy diagnostic times and inter-reader variability.
Amid these developments, the recently introduced AI-based 바카라사이트 소개 diagnostic technology is anticipated to drive a paradigm shift in 바카라사이트 소개 diagnosis and treatment. By supporting clinicians in achieving more accurate interpretations and improving diagnostic efficiency, this technology enables faster and more precise 바카라사이트 소개 assessments through the application of AI.
Through this agreement, AstraZeneca Korea will collaborate to facilitate the successful introduction and clinical implementation of ‘Qanti IHC,’ Aivi’s AI-based biomarker quantification solution for HER2 diagnosis, at medical institutions in Korea. In addition, the two parties plan to explore joint research projects aimed at validating the clinical utility of AI-driven HER2 diagnostic technology and will cooperate in generating real-world evidence to support its adoption.
“Our commitment extends beyond the introduction of innovative medicines to offering more effective treatment options for cancer patients in Korea. We will continue to pursue the implementation of patient-centered solutions throughout the entire process of care, from diagnosis to treatment,” stated Chon Se-hwan, Country President of AstraZeneca Korea.
“Through this collaboration, we aim to introduce AI-based diagnostic technology that aligns with emerging classification systems, such as HER2 low expression, into the domestic clinical setting, thereby laying the foundation for more patients to access timely and appropriate treatment,” Chon further commented.
“With the increasing subdivision of the HER2 classification system, particularly in breast cancer, the role of AI technology in supporting medical professionals with precise interpretation, especially in distinguishing subtle differences in staining, is expected to become increasingly important,” expressed Lee Dae-hong, CEO of Aivis. “Moving forward, our company will strive to alleviate the diagnostic burden on medical professionals and enhance diagnostic efficiency through AI-driven HER2 diagnostic solutions, ultimately enabling cancer patients in Korea to receive more effective treatments based on accurate diagnoses,” he added.